Journal: bioRxiv

Article Title: Adjuvant Discovery via a High Throughput Screen using Human Primary Mononuclear Cells

doi: 10.1101/2022.06.17.496630

Figure Lengend Snippet: A. Distribution of z scores, indicating induction of the cytokines (IFN, IL-10, and TNF). B. Distribution of z scores, representing the percentage of monocytes with activated HLA-DR and/or CD80/86 receptors. C. Distribution of z scores, representing the percentage of T-Cells with activated Ox40 receptors. D. Distribution of z scores, representing the percentage of B-Cells with activated HLA-DR and/or CD80/86 receptors. E. graphical representation of small molecule hit rate in varying number of donors. natural log of hit rate. F. Strong negative correlation between number of donors. Each dot represents one of the 2,296 compounds from the primary screen. The dashed line represents the donor threshold of a z score of 2 and representative z scores were chosen such that any compound above the threshold represents a hit in the screen.

Article Snippet: CD134 (OX40) Antibody, anti-human, APC, REAfinity TM (Clone- REA621) , Miltenyi Biotec , Order Number: 130-122-227.

Techniques:

Journal: bioRxiv

Article Title: Adjuvant Discovery via a High Throughput Screen using Human Primary Mononuclear Cells

doi: 10.1101/2022.06.17.496630

Figure Lengend Snippet: Key resource table

Article Snippet: CD134 (OX40) Antibody, anti-human, APC, REAfinity TM (Clone- REA621) , Miltenyi Biotec , Order Number: 130-122-227.

Techniques: Recombinant, Sterility, Injection, Modification, Staining, Saline, Enzyme-linked Immunosorbent Assay, Multiplex Assay, Software

Journal: Pharmaceutics

Article Title: Curcumin Enhances the Abscopal Effect in Mice with Colorectal Cancer by Acting as an Immunomodulator

doi: 10.3390/pharmaceutics15051519

Figure Lengend Snippet: Biodistribution results of 111 In-anti-OX40 mAb in mice receiving different treatments. Mice were euthanized 48 h after being injected with 111 In-anti-OX40 mAb, designated organs/tissues were collected, and their radioactivity was counted using a gamma counter. Except for blood, the liver, spleen, and tumors showed higher relative radioactivity than other organs. The COMB group had the highest spleen and tumor uptakes among all the groups. a, compared with the CTRL group; b, compared with the Curcumin group; c, compared with the RT group; 1, p < 0.05; 2, p < 0.01.

Article Snippet: Prior to the indium-111 radiolabeling, anti-OX40 mAb (#BE0031, clone OX86, BioXCell, Lebanon, NH, USA) was resuspended in PBS at 0.5 mg/mL and then incubated with fivefold excess DOTA-NHS ester (#HY-128890, MedChemExpress, Monmouth Junction, NJ, USA) at 4 °C overnight.

Techniques: Injection, Radioactivity

Journal: Molecules

Article Title: Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model

doi: 10.3390/molecules26123744

Figure Lengend Snippet: Figure 1. Combined treatment with OX40 agonist and PD1 inhibitor antibodies following VTP therapy suppresses primary tumor growth and improves survival. Percent survival of mice plotted by Kaplan-Meier methods (p < 0.0001).

Article Snippet: In the OX40 agonist subgroups, InVivoPlus antimouse OX40 CD134-Clone: OX-86 (500 mg/kg, Bioxcell, West Lebanon, NH, USA) was injected IP in a single dose on day 1 after VTP.

Techniques:

Journal: Molecules

Article Title: Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model

doi: 10.3390/molecules26123744

Figure Lengend Snippet: Figure 2. Adding PD-1 inhibitor and OX40 agonist to VTP therapy increases T cell infiltration and activation into MB-49 UTUC allografts at 7 days post-treatment and increases CD4+ and CD8+ T cell infiltration into MB-49 UTUC allografted tumors. (A) Heat map showing the mean frequency of each cell population as measured by flow cytometry in control and treated tumors. Each box represents the mean percentage of positive cells among the parent cell population, i.e., CD45+ among live cells, CD4+ or CD8+ cells among CD45+ cells, Foxp3+ Tregs or Teff among CD4+ cells, CD25+/Foxp3+

Article Snippet: In the OX40 agonist subgroups, InVivoPlus antimouse OX40 CD134-Clone: OX-86 (500 mg/kg, Bioxcell, West Lebanon, NH, USA) was injected IP in a single dose on day 1 after VTP.

Techniques: Activation Assay, Cytometry, Control

Journal: Molecules

Article Title: Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model

doi: 10.3390/molecules26123744

Figure Lengend Snippet: Figure 3. Adding PD-1 Inhibitor and OX40 agonist to VTP therapy increases T cell infiltration and activation compared to VTP alone, into MB-49 UTUC allografts at 7 days post-treatment. Representative flow cytometry plots showing the percentage of CD4+ and CD8+ cells among CD45+ cells (top row), Ki67+ in CD4+ (second row), Ki67+ in CD8+ (third row), Foxp3+ Tregs and Foxp3−Teff in CD4+ (fourth row), and GrzB+ in CD8+ T cells (bottom row) in control and treated tumors analyzed 7 days after treatment. A fluorescent minus one (FMO) sample was included for each marker as a negative control for gating.

Article Snippet: In the OX40 agonist subgroups, InVivoPlus antimouse OX40 CD134-Clone: OX-86 (500 mg/kg, Bioxcell, West Lebanon, NH, USA) was injected IP in a single dose on day 1 after VTP.

Techniques: Activation Assay, Flow Cytometry, Control, Marker, Negative Control